Mylan eyes 'all alternatives' as quarterly profit falls short

Mylan eyes 'all alternatives' as quarterly profit falls short


Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers. "We are evaluating all alternatives," Chief Executive Officer Heather Bresch said on a conference call with analysts.



from Biotech News